DALLAS, February 24, 2015 /PRNewswire/ --
RnRMarketResearch.com adds "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015" to its store. This report provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)'s therapeutic pipeline.
The report "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). Acute kidney failure is the unexpected damage to the kidneys that causes them to stop working properly. Acute kidney failure can lead to increased risk of infection and death. Major causes of acute kidney failure include burns, shock, drug toxicity, sepsis, trauma and severe diarrhea. Symptoms of acute kidney injury may include nausea, vomiting, feeling drowsy, difficulty to paying attention, high blood pressure, nosebleeds, seizures, bruising easily, persistent hiccups, little or no urine and numbness. Treatment will depend on the cause of acute kidney failure.
The report has complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269544 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015 report include ACROVIS biostructures GmbH, Adrenomed AG, Am-Pharma B.V., Angion Biomedica Corp., Bolder Biotechnology, Inc., Cellmid Limited, DiaMedica Inc., Digna Biotech, S.L., F. Hoffmann-La Roche Ltd., G1 Therapeutics, Inc., Hadasit Medical Research Services & Development Ltd, Kringle Pharma, Inc., NephroGenex, Inc., Noorik Biopharmaceuticals AG, Nyken BV, Opsona Therapeutics Ltd., Quark Pharmaceuticals, Inc., STATegics, Inc., Thrasos, Inc., Torrent Pharmaceuticals Limited.
Drugs profile discussed in this report include adrecizumab, BB-3, BBT-030, BBT-045, CAB-101, cardiotrophin-1, Cell Therapy to Activate Wnt7b for Kidney Injury, CXA-10, DM-199, HYPER-IL-6, KP-100IT, MTP-131, N-003, NOXD-21, NYK-1341, OPN-305, Pyridoxamine Dihydrochloride, QPI-1002, R-190, Recombinant Human Alkaline Phosphatase, RO-6839328, Small Molecule to Activate Heat Shock Protein 70 (Hsp70) for Delayed Graft Function, Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer, Small Molecule to Inhibit HDAC for Acute Kidney Injury, Small Molecules for Acute Renal Failure, STSE-15, THR-184, TRC-160334.
Featured News & Press Releases cover by this report include: Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury; Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury; Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury; Jul 01, 2014: Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients; May 01, 2014: Complexa Initiates First Clinical Trial of CXA-10 for Acute Kidney Injury; Mar 26, 2014: AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury; Feb 04, 2014: FDA Grants Thrasos Fast Track Designation for THR-184 in Acute Kidney Injury; Jan 28, 2014: American Journal of Kidney Disease publishes review article of Alkaline Phosphatase; Nov 08, 2013: AM-Pharma Presents Positive Data from recAP Preclinical Study at ASN Meeting; Sep 23, 2013: AM-Pharma Returns to Clinic with Phase I Trial of New Recombinant Human Alkaline Phosphatase to Treat Acute Kidney Injury.
Scope of Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015 covers: a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury); reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type; Latest news and deals relating related to pipeline products.
Explore more reports on Renal therapeutics @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/kidney/kidneyrenal-therapeutics .
Get more reports on Renal therapeutics:
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). Companies discuss in the report include Hospira, Inc., AstraZeneca PLC, Eli Lilly and Company, Quark Pharmaceuticals, Inc., Astellas Pharma Inc., OPKO Health, Inc., Toray Industries, Inc., Evotec AG, NPS Pharmaceuticals, Inc., La Jolla Pharmaceutical Company, Alexion Pharmaceuticals, Inc., AFFiRiS AG, Acceleron Pharma, Inc., Nippon Zoki Pharmaceutical Co., Ltd., Catabasis Pharmaceuticals, Inc., Angion Biomedica Corp., Concert Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., TRACON Pharmaceuticals, Inc., Stelic Institute & Co., Vicore Pharma AB, Otsuka Holdings Co., Ltd., Sphaera Pharma Pvt. Ltd., Multi Gene Vascular Systems Ltd, Bio-inRen, Red Glead Discovery AB.
Kidney Transplantation - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discuss in the report include Kyowa Hakko Kirin Co., Ltd., GlaxoSmithKline plc, Quark Pharmaceuticals, Inc., Pharming Group N.V., Grifols, S.A., Novartis AG, Astellas Pharma Inc., Shire Plc, Veloxis Pharmaceuticals A/S, La Jolla Pharmaceutical Company, Hansa Medical AB, Digna Biotech, S.L., Viron Therapeutics, Inc., Opsona Therapeutics Ltd., Angion Biomedica Corp., NovImmune SA, Tolera Therapeutics, Inc., Bio-inRen.
Polycystic Kidney Disease - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease. Companies discuss in the report include Plexxikon Inc., Ipsen S.A., Pfizer Inc., Synta Pharmaceuticals Corp., Metabolic Solutions Development Company, LLC, IC-MedTech, Inc., Endocyte, Inc., ManRos Therapeutics, DiscoveryBiomed, Inc., Otsuka Holdings Co., Ltd., Kadmon Corporation, LLC.
About Us:
RnRMarketResearch.com is a database of selected syndicated market research reports for global and regional industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 [email protected]
SOURCE RnR Market Research
Advertisement
RnRMarketResearch.com adds "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015" to its store. This report provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)'s therapeutic pipeline.
Advertisement
The report "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). Acute kidney failure is the unexpected damage to the kidneys that causes them to stop working properly. Acute kidney failure can lead to increased risk of infection and death. Major causes of acute kidney failure include burns, shock, drug toxicity, sepsis, trauma and severe diarrhea. Symptoms of acute kidney injury may include nausea, vomiting, feeling drowsy, difficulty to paying attention, high blood pressure, nosebleeds, seizures, bruising easily, persistent hiccups, little or no urine and numbness. Treatment will depend on the cause of acute kidney failure.
The report has complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269544 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015 report include ACROVIS biostructures GmbH, Adrenomed AG, Am-Pharma B.V., Angion Biomedica Corp., Bolder Biotechnology, Inc., Cellmid Limited, DiaMedica Inc., Digna Biotech, S.L., F. Hoffmann-La Roche Ltd., G1 Therapeutics, Inc., Hadasit Medical Research Services & Development Ltd, Kringle Pharma, Inc., NephroGenex, Inc., Noorik Biopharmaceuticals AG, Nyken BV, Opsona Therapeutics Ltd., Quark Pharmaceuticals, Inc., STATegics, Inc., Thrasos, Inc., Torrent Pharmaceuticals Limited.
Drugs profile discussed in this report include adrecizumab, BB-3, BBT-030, BBT-045, CAB-101, cardiotrophin-1, Cell Therapy to Activate Wnt7b for Kidney Injury, CXA-10, DM-199, HYPER-IL-6, KP-100IT, MTP-131, N-003, NOXD-21, NYK-1341, OPN-305, Pyridoxamine Dihydrochloride, QPI-1002, R-190, Recombinant Human Alkaline Phosphatase, RO-6839328, Small Molecule to Activate Heat Shock Protein 70 (Hsp70) for Delayed Graft Function, Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer, Small Molecule to Inhibit HDAC for Acute Kidney Injury, Small Molecules for Acute Renal Failure, STSE-15, THR-184, TRC-160334.
Featured News & Press Releases cover by this report include: Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury; Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury; Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury; Jul 01, 2014: Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients; May 01, 2014: Complexa Initiates First Clinical Trial of CXA-10 for Acute Kidney Injury; Mar 26, 2014: AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury; Feb 04, 2014: FDA Grants Thrasos Fast Track Designation for THR-184 in Acute Kidney Injury; Jan 28, 2014: American Journal of Kidney Disease publishes review article of Alkaline Phosphatase; Nov 08, 2013: AM-Pharma Presents Positive Data from recAP Preclinical Study at ASN Meeting; Sep 23, 2013: AM-Pharma Returns to Clinic with Phase I Trial of New Recombinant Human Alkaline Phosphatase to Treat Acute Kidney Injury.
Scope of Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015 covers: a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury); reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type; Latest news and deals relating related to pipeline products.
Explore more reports on Renal therapeutics @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/kidney/kidneyrenal-therapeutics .
Get more reports on Renal therapeutics:
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). Companies discuss in the report include Hospira, Inc., AstraZeneca PLC, Eli Lilly and Company, Quark Pharmaceuticals, Inc., Astellas Pharma Inc., OPKO Health, Inc., Toray Industries, Inc., Evotec AG, NPS Pharmaceuticals, Inc., La Jolla Pharmaceutical Company, Alexion Pharmaceuticals, Inc., AFFiRiS AG, Acceleron Pharma, Inc., Nippon Zoki Pharmaceutical Co., Ltd., Catabasis Pharmaceuticals, Inc., Angion Biomedica Corp., Concert Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., TRACON Pharmaceuticals, Inc., Stelic Institute & Co., Vicore Pharma AB, Otsuka Holdings Co., Ltd., Sphaera Pharma Pvt. Ltd., Multi Gene Vascular Systems Ltd, Bio-inRen, Red Glead Discovery AB.
Kidney Transplantation - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discuss in the report include Kyowa Hakko Kirin Co., Ltd., GlaxoSmithKline plc, Quark Pharmaceuticals, Inc., Pharming Group N.V., Grifols, S.A., Novartis AG, Astellas Pharma Inc., Shire Plc, Veloxis Pharmaceuticals A/S, La Jolla Pharmaceutical Company, Hansa Medical AB, Digna Biotech, S.L., Viron Therapeutics, Inc., Opsona Therapeutics Ltd., Angion Biomedica Corp., NovImmune SA, Tolera Therapeutics, Inc., Bio-inRen.
Polycystic Kidney Disease - Pipeline Review, H2 2014
This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease. Companies discuss in the report include Plexxikon Inc., Ipsen S.A., Pfizer Inc., Synta Pharmaceuticals Corp., Metabolic Solutions Development Company, LLC, IC-MedTech, Inc., Endocyte, Inc., ManRos Therapeutics, DiscoveryBiomed, Inc., Otsuka Holdings Co., Ltd., Kadmon Corporation, LLC.
About Us:
RnRMarketResearch.com is a database of selected syndicated market research reports for global and regional industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.
Contact: Ritesh Tiwari TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252 Tel: +1-888-391-5441 [email protected]
SOURCE RnR Market Research
